Clostridium Infections, Inflammatory Bowel Diseases
Conditions
Brief summary
In recent years, the incidence of Inflammatory Bowel Disease (IBD) has been increasing in China, which poses great challenges and burdens to the medical community due to its unknown etiology, recurrence and incurability. Co-infection is one of the important causes in IBD development. IBD accompanied with Clostridium Difficile Infection (CDI) can significantly decrease the treatment efficiency, leading to increased surgical rate, increased mortality, prolonged hospital stay, and increased hospital costs. Recently, several Chinese clinical guidelines about IBD or CDI have been published, but these guidelines are mainly based on the foreign studies. Compared with the developed countries, the lack of multi-center, large-scale and multi-test clinical trials and cohort studies caused limited understanding for IBD-CDI in China. Therefore, it is of great importance to carry out the multi-center clinical trials and analysis on IBD-CDI to improve the diagnostic and therapeutic efficiency in IBD-CDI patients Objective: 1. To evaluate the prevalence rate of IBD-CDI in Chinese adults in China based on the multi-center clinical trials.. 2. To analyze the related risk factors of IBD-CDI in China based on the multi-center clinical trials. 3. To analyze the intestinal flora of IBD-CDI patients via high-throughput sequencing.
Interventions
None listed
Sponsors
Xijing Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* 1.Inpatients with diagnostic criteria for ulcerative colitis and Crohn's disease in accordance with the consensus opinion on the diagnosis and treatment of inflammatory bowel disease in China in 2012 * 2.Willing to participate in the study; * 3\. Have the ability to understand and sign informed consent.
Exclusion criteria
* 1.Patients with infectious enteritis, intestinal tuberculosis, lymphoma, Behcet's disease or other intestinal diseases except inflammatory bowel disease; * 2.Pregnant or lactating women; * 3.Severe circulatory system, respiratory system, blood system, immune system, urinary system and other combined diseases or serious psychosomatic diseases.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Prevalence rate of IBD with CDI in Chinese adults | 3 years | To analyze the prevalence rate of IBD with CDI in Chinese adults based on the multicenter clinical trials. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Risk factors of IBD with CDI in China | 3 years | To analyze the related risk factors of IBD with CDI in China based on the multicenter clinical trials. Including demographic data,severity of disease（Mayo score for ulcerative colitis and CDAI score for CD),laboratory results（ESR、CRP、WBC、Hb、RBC）and combination therapy. |
| Gut microbiota in patients with IBD-CDI，IBD and healthy volunteers by 16S rDNA sequencing | 3 years | To analyze the gut microbiota with IBD-CDI，IBD and healthy volunteers.Including fecal flora composition and the abundance analysis by 16S rDNA sequencing. |
Other
| Measure | Time frame | Description |
|---|---|---|
| Using PCR and ELISA to detect the positive rate of clostridium difficile in patients with IBD and healthy volunteers | 3 years | To compare the positive rate of clostridium difficile in patients with IBD and healthy volunteers by PCR and ELISA. |
Countries
China
Contacts
Primary ContactYujie Zhang, MD
Outcome results
None listed